A PHASE IB STUDY OF SECOND-LINE THERAPY WITH PANITUMUMAB, IRINOTECAN AND EVEROLIMUS (PIE) IN METASTATIC COLORECTAL CANCER (mCRC) WITH KRAS WILD TYPE (WT) (#430)